www.vaxart.com
The @The White House summit on next-gen #vaccines stressed the need for mucosal immune responses, which is exactly what the Vaxart investigational vaccine generated in a Phase 2 clinical trial.
part1: [ Ссылка ]...
The world needs next-gen vaccines and Congress can help speed up their development.
Vaxart is the first company to report positive data from a Phase 2 study of an oral next-gen #vaccine that generates a mucosal immunogenic response.
The P2 data showed that the investigational vaccine is well-tolerated and cross-reactive, showed cross-reactivity with the Omicron variants and other coronaviruses. By harnessing more of our immune system this vaccine may ultimately prove to offer broader, longer protection against current and future variants.
The Vaxart Phase 2 data shows that the investigational vaccine induces potent antibody and T-cell responses while stimulating both serum and mucosal immunogenic response.
The positive data from Phase 2 study further reinforces the potentially transformative effect the oral vaccine platform can have in the global fight against infectious diseases.
When it comes to oral tableted vaccines that are progressing through clinical trials, it is clear that Vaxart is the leader.
#covid19 #covid #covidvaccine #vaccination #health #virus #america #world @World Health Organization (WHO)

свернуть